CONFERENCE PROGRAM

FRIDAY, SEPTEMBER 21

3:00 p.m.-7:00 p.m.	**REGISTRATION** Foyer

6:00 p.m.-8:10 p.m. **WELCOME AND KEYNOTE LECTURES**
Salon A-E

Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

6:00 p.m.-6:10 p.m. **Welcome from Cochairs**
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

6:10 p.m.-6:20 p.m. **Welcome from Lead Supporters**
Kerri Kaplan, Lustgarten Foundation, Woodbury, NY
Julie M. Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA

6:20 p.m.-7:00 p.m. **Precision medicine for pancreas cancer: New approaches from old**
Ben Z. Stanger, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

7:00 p.m.-7:40 p.m. **Designing clinical trials in pancreatic cancer: Challenges and innovations**
Andrew H. Ko, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

7:40 p.m.-8:10 p.m. **Outcomes of surveillance and treatment of high-risk individuals**
Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD

8:15 p.m.-10:00 p.m. **OPENING RECEPTION**
Salon F-K

SATURDAY, SEPTEMBER 22

7:30 a.m.-8:30 a.m. **BREAKFAST AND NETWORKING ROUNDTABLES**
Salon F-K

Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain
Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX
Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, MA

8:30 a.m.-10:00 a.m.	**PLENARY SESSION 1: IMAGING/DIAGNOSTICS** Salon A-E

Session Chair: Julie L. Sutcliffe, University of California, Davis, Davis, CA

8:30 a.m.-9:00 a.m.	**Pancreas imaging 2018: MDCT, 3D rendering, and deep learning** Elliot K. Fishman, Johns Hopkins Hospital, Baltimore, MD
9:00 a.m.-9:30 a.m.	**Immunologic properties of biophysical subtypes of pancreatic cancer: Implications for therapeutic selection** Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX
9:30 a.m.-10:00 a.m.	**Using artificial intelligence to extract latent biomarkers from clinical imaging of the pancreas** Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, MA

10:00 a.m.-10:30 a.m.	**BREAK** Foyer

10:30 a.m.-12:30 p.m.	**PLENARY SESSION 2: THE CHANGING PRACTICE OF GENETIC TESTING** Salon A-E

Session Chair: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

10:30 a.m.-11:00 a.m.	**Risk estimates for pancreatic cancer predisposition genes** Fergus J. Couch, Mayo Clinic, Rochester, MN
11:00 a.m.-11:30 a.m.	**Therapeutic implications of germline variants in pancreatic cancer** Maeve Lowery, Trinity College Dublin, Dublin, Ireland
11:30 a.m.-12:00 p.m.	**Genetic predisposition to pancreatic cancer: Who should be tested, and how?** Elena M. Stoffel, University of Michigan, Ann Arbor, MI
12:00 p.m.-12:30 p.m.	**Identification and management of healthy individuals with pancreatic cancer gene mutations** Sapna Syngal, Dana-Farber Cancer Institute, Boston, MA

12:30 p.m.-3:00 p.m.	**POSTER SESSION A / LUNCH** Salon F-K

3:15 p.m.-4:45 p.m.	**PLENARY SESSION 3: BLOOD-BASED EARLY DETECTION** Salon A-E

Session Chair: Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD

3:15 p.m.-3:45 p.m.	**Multi-analyte blood test for the detection of cancer** Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

3:45 p.m.-4:15 p.m.	**Advancing a plasma marker panel to detect pancreatic ductal adenocarcinoma** Kenneth S. Zaret, University of Pennsylvania, Philadelphia, PA
4:15 p.m.-4:45 p.m.	**Multiplex enrichment and detection of KRAS mutations in liquid biopsy samples using digital droplet preamplification** Erica D. Pratt, University of Minnesota, Minneapolis, MN
4:45 p.m.-5:00 p.m.	**BREAK** Foyer
5:00 p.m.-6:30 p.m.	**PLENARY SESSION 4: IMMUNOLOGY AND IMMUNOTHERAPY** Salon A-E
	Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA
5:00 p.m.-5:30 p.m.	**Immunotherapy strategies in PDAC** Manuel Hidalgo
5:30 p.m.-6:00 p.m.	**Decoding the T cell-antigen landscape of long-term pancreatic cancer survivors** Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY
6:00 p.m.-6:30 p.m.	**Innate and adaptive immunity in the tumor microenvironment of pancreas cancer** David C. Linehan, University of Rochester, Rochester, NY
6:30 p.m.-	**EVENING OFF / DINNER ON OWN**

SUNDAY, SEPTEMBER 23

7:30 a.m.-8:30 a.m.	**BREAKFAST AND NETWORKING ROUNDTABLES** Salon F-K

Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY
Kerri Kaplan, Lustgarten Foundation, Woodbury, NY
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX
Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH
David C. Linehan, University of Rochester, Rochester, NY
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

8:30 a.m.-10:00 a.m. **PLENARY SESSION 5: TUMOR MICROENVIRONMENT**
Salon A-E

Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, CA

8:30 a.m.-9:00 a.m. **The tumor microenvironment of primary and metastatic pancreatic adenocarcinoma: Similarities, differences, and response to treatment**
Michael A. Hollingsworth, UNMC Eppley Institute for Research in Cancer, Omaha, NE

9:00 a.m.-9:30 a.m. **Fibroblast heterogeneity in pancreatic cancer**
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, NY

9:30 a.m.-10:00 a.m. **Exploiting the complex stromal biology of pancreas cancer**
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA

10:00 a.m.-10:30 a.m. **BREAK**
Foyer

10:30 a.m.-12:30 p.m. **PLENARY SESSION 6: RAS / SIGNALING / ONCOGENES**
Salon A-E

Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

10:30 a.m.-11:00 a.m. **Engineered exosomes for precision therapy of pancreatic cancer**
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX

11:00 a.m.-11:30 a.m. **Treatment of oncogenic activation of ERK in human cancer**
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m.-12:00 p.m. **Targeting cancer-specific vulnerabilities**
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 p.m.-12:30 p.m. **Complete regression of advanced pancreatic ductal adenocarcinomas in genetically engineered mice upon combined inhibition of EGFR and c-RAF signaling pathways**
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain

12:30 p.m.-2:30 p.m. **FREE TIME / LUNCH ON OWN**

2:45 p.m.-4:45 p.m. **PLENARY SESSION 7: METABOLISM AND METABOLOMICS**
Salon A-E

Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, CA

2:45 p.m.-3:15 p.m. **Epigenetic control of PDA genomic networks**
Ronald M. Evans

3:15 p.m.-3:45 p.m. **Title to be announced**
Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, MA

CONFERENCE PROGRAM

3:45 p.m.-4:15 p.m.	**Targeting cysteine metabolism in pancreatic cancer** Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY
4:15 p.m.-4:45 p.m.	**Metabolic vulnerabilities—targeting oxidative phosphorylation** Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 p.m.-5:40 p.m.	**SPOTLIGHT ON PROFFERED PAPERS** Salon A-E
5:00 p.m.-5:08 p.m.	**Post-translational O GlcNAcylation of SOX2 controls its tumor initiation properties in pancreatic cancer*** Nikita Sharma, University of Miami, Miami, FL
5:08 p.m.-5:16 p.m.	**Identification of functional heterogeneity of fibroblasts and their impact on riot immunity in pancreatic cancer*** Josephine Darpolor, The University of Texas MD Anderson Cancer Center, Houston, TX
5:16 p.m.-5:24 p.m.	**Lysyl oxidases suppress pancreatic cancer progression by inhibiting focal adhesion kinase signaling*** Mario Shields, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
5:24 p.m.-5:32 p.m.	**PDAC development and progression is dependent upon SHP2*** Michael VanSaun, University of Miami, Miami, FL
5:32 p.m.-5:40 p.m.	**RNA profiling and the impact of current classifiers on survival in patients receiving combination chemotherapy on the COMPASS trial*** Grainne O'Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada

5:45 p.m.-8:00 p.m.	**POSTER SESSION B / RECEPTION** Salon F-K

8:00 p.m.-	**EVENING OFF / DINNER ON OWN**

MONDAY, SEPTEMBER 24

7:30 a.m.-8:30 a.m.	**BREAKFAST** Salon F-K

Short talk from proffered abstract

8:30 a.m.-10:00 a.m.	**PLENARY SESSION 8: PRECISION MEDICINE** Salon A-E

Session Chair: Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH

8:30 a.m.-9:00 a.m.	**Genomic and functional profiling of advanced pancreatic cancer to enable precision medicine** Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
9:00 a.m.-9:30 a.m.	**Using pancreatic organoids to model, detect, and treat cancer** Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA
9:30 a.m.-10:00 a.m.	**Altered mRNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer** Lusia Escobar-Hoyos, Memorial Sloan Kettering Cancer Center, New York, NY
10:00 a.m.-10:15 a.m.	**BREAK** Foyer
10:15 a.m.-11:45 a.m.	**PLENARY SESSION 9: LOCAL-REGIONAL THERAPIES/MANAGEMENT OF LOCAL DISEASE** Salon A-E

Session Chair: Susan Tsai, Medical College of Wisconsin, Milwaukee, WI

10:15 a.m.-10:45 a.m.	**Pancreas SBRT: Ablation versus immune potentiation** Joseph M. Herman, The University of Texas MD Anderson Cancer Center, Houston, TX
10:45 a.m.-11:15 a.m.	**Why operable pancreatic cancer is the best model for translational research: Treatment sequencing, assessment of response, and results with innovative multimodality therapy** Douglas B. Evans, Medical College of Wisconsin, Milwaukee, WI
11:15 a.m.-11:45 a.m.	**New directions in adjuvant and neoadjuvant therapy for resectable pancreas ductal adenocarcinoma** Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY
11:45 a.m.-12:45 p.m.	**PANEL DISCUSSION ON CLINICAL TRIALS** Salon A-E

Moderator: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

Panelists
James L. Abbruzzese, Duke University Medical Center, Durham, NC
Wen Wee Ma, Mayo Clinic, Rochester, MN
Lynn M. Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, CA
Diane M. Simeone, New York University, New York, NY
Andrea Wang-Gillam, Washington University in St.Louis, St. Louis, MO

12:45 p.m.	**DEPARTURE**